GT BIOPHARMA, INC. Investing Cash Flow
GT BIOPHARMA, INC. (GTBP) reported Investing Cash Flow of $12.89 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-03-06
- GT BIOPHARMA, INC. net cash provided by (used in) investing activities for the quarter ending 2024-12-31 was $1.00K, a 99.79% decline year-over-year.
- GT BIOPHARMA, INC. net cash provided by (used in) investing activities for the quarter ending 2024-09-30 was -$1.00K, a 100.05% decline year-over-year.
- GT BIOPHARMA, INC. net cash provided by (used in) investing activities for the quarter ending 2024-06-30 was $7.86M, a 195.78% increase year-over-year.
- GT BIOPHARMA, INC. net cash provided by (used in) investing activities for the quarter ending 2024-03-31 was $5.03M.
- GT BIOPHARMA, INC. net cash provided by (used in) investing activities for fiscal 2024 was $12.89M.
- GT BIOPHARMA, INC. net cash provided by (used in) investing activities for fiscal 2023 was -$2.01M, a 116.54% decline from fiscal 2022.
- GT BIOPHARMA, INC. net cash provided by (used in) investing activities for fiscal 2022 was $12.14M.
- GT BIOPHARMA, INC. net cash provided by (used in) investing activities for fiscal 2021 was -$23.04M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2024-12-31 | $1.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-06 | $7.86M derived: sum of 3 quarters · filed 2026-03-06 | $12.89M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$1.00K derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2026-03-06 | $7.86M derived: sum of 2 quarters · filed 2026-03-06 | $12.89M 10-Q/A · filed 2026-03-06 | $13.37M derived: sum of 4 quarters · filed 2026-03-06 |
| 2024-06-30 | $7.86M derived: 10-Q/A 6 month − 10-Q 3 month · filed 2026-03-06 | $12.89M 10-Q/A · filed 2026-03-06 | $13.37M derived: sum of 3 quarters · filed 2026-03-06 | $15.22M derived: sum of 4 quarters · filed 2026-03-06 |
| 2024-03-31 | $5.03M 10-Q · filed 2025-05-15 | $5.51M derived: sum of 2 quarters · filed 2025-05-15 | $7.36M derived: sum of 3 quarters · filed 2025-05-15 | $10.01M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $478.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $2.32M derived: sum of 2 quarters · filed 2025-02-21 | $4.98M derived: sum of 3 quarters · filed 2025-02-21 | -$2.01M 10-K · filed 2025-02-21 |
| 2023-09-30 | $1.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $4.50M derived: sum of 2 quarters · filed 2024-11-14 | -$2.49M 10-Q · filed 2024-11-14 | $5.02M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $2.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$4.33M 10-Q · filed 2024-08-14 | $3.17M derived: sum of 3 quarters · filed 2024-08-14 | $3.20M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$6.99M 10-Q · filed 2024-05-15 | $517.00K derived: sum of 2 quarters · filed 2024-05-15 | $542.00K derived: sum of 3 quarters · filed 2024-05-15 | $1.62M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $7.51M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $7.53M derived: sum of 2 quarters · filed 2024-03-26 | $8.61M derived: sum of 3 quarters · filed 2024-03-26 | $12.14M 10-K · filed 2024-03-26 |
| 2022-09-30 | $25.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $1.11M derived: sum of 2 quarters · filed 2023-11-01 | $4.64M 10-Q · filed 2023-11-01 | $7.63M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | $1.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $4.61M 10-Q · filed 2023-08-07 | $7.61M derived: sum of 3 quarters · filed 2023-08-07 | |
| 2022-03-31 | $3.53M 10-Q · filed 2023-05-15 | $6.52M derived: sum of 2 quarters · filed 2023-05-15 | ||
| 2021-12-31 | $2.99M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$23.04M 10-K · filed 2023-03-30 | ||
| 2021-09-30 | -$26.03M 10-Q · filed 2022-10-31 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-04-16 | $0.00 derived: sum of 2 quarters · filed 2021-04-16 | $0.00 10-K · filed 2021-04-16 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q/A 6 month · filed 2020-11-13 | $0.00 10-Q · filed 2020-11-13 | ||
| 2020-06-30 | $0.00 10-Q/A · filed 2020-08-18 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-04-16 | $200.00K derived: sum of 2 quarters · filed 2021-04-16 | $200.00K derived: sum of 3 quarters · filed 2021-04-16 | $200.00K 10-K · filed 2021-04-16 |
| 2019-09-30 | $200.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2020-11-13 | $200.00K derived: sum of 2 quarters · filed 2020-11-13 | $200.00K 10-Q · filed 2020-11-13 | $168.00K derived: sum of 4 quarters · filed 2020-11-13 |
| 2019-06-30 | $0.00 derived: 10-Q/A 6 month − 10-Q 3 month · filed 2020-08-18 | $0.00 10-Q/A · filed 2020-08-18 | -$32.00K derived: sum of 3 quarters · filed 2020-08-18 | -$34.00K derived: sum of 4 quarters · filed 2020-08-18 |
| 2019-03-31 | $0.00 10-Q · filed 2019-05-15 | -$32.00K derived: sum of 2 quarters · filed 2020-03-27 | -$34.00K derived: sum of 3 quarters · filed 2020-03-27 | -$34.00K derived: sum of 4 quarters · filed 2020-03-27 |
| 2018-12-31 | -$32.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | -$34.00K derived: sum of 2 quarters · filed 2020-03-27 | -$34.00K derived: sum of 3 quarters · filed 2020-03-27 | -$36.00K 10-K · filed 2020-03-27 |
| 2018-09-30 | -$2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | -$2.00K derived: sum of 2 quarters · filed 2019-11-14 | -$4.00K 10-Q · filed 2019-11-14 | -$8.00K derived: sum of 4 quarters · filed 2019-11-14 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | -$2.00K 10-Q · filed 2019-08-14 | -$6.00K derived: sum of 3 quarters · filed 2019-08-14 | -$6.00K derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-03-31 | -$2.00K 10-Q · filed 2019-05-15 | -$6.00K derived: sum of 2 quarters · filed 2019-05-15 | -$6.00K derived: sum of 3 quarters · filed 2019-05-15 | -$6.00K derived: sum of 4 quarters · filed 2019-05-15 |
| 2017-12-31 | -$4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-29 | -$4.00K derived: sum of 2 quarters · filed 2019-03-29 | -$4.00K derived: sum of 3 quarters · filed 2019-03-29 | -$4.00K 10-K · filed 2019-03-29 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $0.00 derived: sum of 2 quarters · filed 2018-11-14 | $0.00 10-Q · filed 2018-11-14 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | $0.00 10-Q · filed 2018-08-14 | ||
| 2017-03-31 | $0.00 10-Q · filed 2018-05-15 | |||
| 2016-12-31 | $0.00 10-K · filed 2018-03-01 | |||
| 2016-06-30 | $0.00 10-Q · filed 2017-08-11 | |||
| 2015-12-31 | -$1.00K 10-K/A · filed 2018-02-28 | |||
| 2014-12-31 | -$6.00K 10-K/A · filed 2018-02-28 | |||
| 2013-12-31 | $0.00 10-K · filed 2015-03-31 | |||
| 2012-12-31 | -$2.00K 10-K · filed 2015-01-08 | |||
| 2011-12-31 | $0.00 10-K · filed 2014-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |